TJ101 / Phrontline Biopharma, Sino Biopharm - LARVOL DELTA

Preliminary safety and pharmacokinetics of TJ101, an EGFR × B7-H3 bispecific antibody-drug conjugate, in patients with advanced solid tumors: results from an ongoing global Phase I study (ESMO 2026) - No abstract available

ADC • Bispecific • Clinical • Metastases • P1 data • PK/PD data • Oncology • Solid Tumor • CD276

Preclinical development of TJ101, a potent bispecific ADC targeting EGFR and B7-H3 for the treatment of solid cancers (AACR 2025) - "In summary, TJ101 is a promising bispecific ADC with highly potent anti-tumor efficacy across multiple solid cancer types and preferable toxicity profiles, enabling an increased therapeutic index. Additionally, the dual-targeting approach of TJ101 offers a significant advantage in overcoming potential tumor resistance that may arise during future clinical applications."

ADC • Bispecific • Preclinical • Breast Cancer • Colon Cancer • Colorectal Cancer • Esophageal Cancer • Genito-urinary Cancer • Head and Neck Cancer • Kidney Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Prostate Cancer • Renal Cell Carcinoma • Small Cell Lung Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • CD276 • EGFR

A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=200 | Recruiting | Sponsor: Phrontline Biopharma

First-in-human • New P1 trial • Esophageal Cancer • Genito-urinary Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Prostate Cancer • Solid Tumor

Phrontline Biopharma Announces First Patient Dosed in Phase 1 Clinical Trial of TJ101 (PRNewswire) - "The Phase 1 study of TJ101 will evaluate its safety, tolerability, pharmacokinetics, and preliminary antitumor activity across multiple solid tumor types."

Trial status • Solid Tumor